News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Bausch & Lomb (BOL) Introduces New PreserVision(R) Eye Vitamin and Mineral Supplement

4/9/2010 9:11:13 AM

MADISON, NJ--(Marketwire - April 09, 2010) -

Bausch + Lomb announces the U.S. launch of PreserVision® Eye Vitamin and Mineral Supplement AREDS 2 formula. This builds on the original, clinically proven Age-Related Eye Disease Study (AREDS) formula, replacing beta-carotene with lutein (10mg) and zeaxanthin (2mg) and adding omega-3 fatty acids (1000 mg) per daily dosage. The product will be on retail shelves in early May, 2010.

Scientific studies show that the inclusion of high levels of omega-3 fatty acids, lutein and zeaxanthin in the diet supports eye health. Age-related macular degeneration (AMD) is the number one cause of severe vision loss and blindness in the United States for people over the age of 50.

The AREDS2® study, which is currently ongoing and expected to complete in 2013, is sponsored by the National Eye Institute/National Institute of Health and is the second nationwide clinical study to determine whether a combination of vitamins and minerals can further slow the progression of vision loss from AMD. PreserVision AREDS 2 formula is one of many formulas that are being evaluated in this study.

About Bausch + Lomb
Bausch + Lomb is dedicated to bringing visionary ideas to eye health. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. The Bausch + Lomb name is one of the best-known and most respected healthcare brands in the world. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 10,000 people worldwide. Its products are available in more than 100 countries. More information is available at

PreserVision is a registered trademark of Bausch & Lomb Incorporated.
AREDS2 is a registered trademark of The U.S. Department of Health and Human Services.

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

News Media Contact:

Laurie Wooding
Global Pharma Communications, Bausch + Lomb
Office 973-360-6418, cell 862-222-7312, or

Read at

comments powered by Disqus